MyFinsight
Home
Blog
About
Contact
Download
Download image
Asia
$76,850K
Europe Excluding
Germany
$2,700K
US
$103,675K
Royalty revenue on sales
of ocrevus-Roche...
$7,500K
Biogen's share of pre-tax
profits in the u.s. for...
$127,800K
Royalty Attributed To
OCREVUS
$385,900K
Non Us
$749,600K
US
$917,700K
Income tax (benefit)
expense
-$7,100K
something is missing
$372,125K
Contract Manufacturing
Royalty And Other...
$183,225K
Alzheimers Collaboration
$44,425K
Revenues From Anti
CD20Therapeutic Programs
$465,150K
Product
$1,667,300K
something is missing
-$56,050K
Net income
attributable to biogen inc
-$48,900K
Net income
$323,225K
Income before income
tax (benefit)...
-$56,000K
Revenues
$2,279,400K
something is missing
-$372,125K
Total cost and expense
$2,335,400K
Restructuring charges
$6,600K
Impairment of rou asset
$13,225K
(gain) loss on fair
value remeasurement...
-$8,400K
Collaboration profit
sharing/(loss reimbursement)
$72,550K
Amortization and impairment
of acquired...
$136,600K
Selling, general and
administrative
$682,500K
Acquired in-process
research and...
$117,950K
Research and development
$509,400K
Cost of sales,
excluding amortization...
$495,500K
Back
Back
Income Statement
source: myfinsight.com
Biogen-svg
BIOGEN INC. (BIIB)
Biogen-svg
BIOGEN INC. (BIIB)